IGMS Stock Overview
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
IGM Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.30 |
| 52 Week High | US$35.98 |
| 52 Week Low | US$12.67 |
| Beta | -0.19 |
| 1 Month Change | 18.11% |
| 3 Month Change | -12.14% |
| 1 Year Change | 25.56% |
| 3 Year Change | -50.81% |
| 5 Year Change | n/a |
| Change since IPO | -8.23% |
Recent News & Updates
Recent updates
Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Jan 05
IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business
Sep 23IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates
Aug 29IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M
Aug 08We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate
Jun 09IGM Biosciences: Interesting Science, Poor Trial Data
Feb 23Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?
Feb 17Here's Why We're Not Too Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Sep 07IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
May 25IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
Feb 08IGM Biosciences reports quick assets and provides business updates
Jan 13Trade Alert: The Independent Director Of IGM Biosciences, Inc. (NASDAQ:IGMS), M. Behrens, Has Just Spent US$4.0m Buying 39% More Shares
Dec 18IGM Bio prices upsized $200M public offering
Dec 09IGM Biosciences proposes public offering
Dec 07IGM Biosciences (IGMS) Investor Presentation - Slideshow
Nov 20Shareholder Returns
| IGMS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.2% | -1.8% | -1.8% |
| 1Y | 25.6% | 1.9% | -10.9% |
Return vs Industry: IGMS exceeded the US Biotechs industry which returned 2.9% over the past year.
Return vs Market: IGMS exceeded the US Market which returned -10.8% over the past year.
Price Volatility
| IGMS volatility | |
|---|---|
| IGMS Average Weekly Movement | 16.2% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: IGMS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: IGMS's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 242 | Fred Schwarzer | https://igmbio.com |
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company’s lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin’s lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia.
IGM Biosciences, Inc. Fundamentals Summary
| IGMS fundamental statistics | |
|---|---|
| Market Cap | US$955.03m |
| Earnings (TTM) | -US$219.17m |
| Revenue (TTM) | US$697.00k |
1,370x
P/S Ratio-4.4x
P/E RatioIs IGMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IGMS income statement (TTM) | |
|---|---|
| Revenue | US$697.00k |
| Cost of Revenue | US$46.42m |
| Gross Profit | -US$45.72m |
| Other Expenses | US$173.45m |
| Earnings | -US$219.17m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.12 |
| Gross Margin | -6,559.25% |
| Net Profit Margin | -31,444.48% |
| Debt/Equity Ratio | 0% |
How did IGMS perform over the long term?
See historical performance and comparison